Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atrial fibrillation
Fierce Pharma
BMS delays key Cobenfy, milvexian readouts amid Q2 beat
BMS lifted its full-year outlook after recording nearly $13 billion in Q2 revenue, which topped Wall Street’s consensus by 10.6%.
Angus Liu
Jul 30, 2026 10:12am
Boston Scientific heart plug stands up to blood thinners at ACC
Mar 30, 2026 11:02am
Abbott's Volt pulsed field ablation system scores FDA approval
Dec 22, 2025 11:48am
Boston Scientific claims EU approval for Farapoint PFA catheter
Dec 2, 2025 12:28pm
Cardiac tech pushes Medtronic's Q2 earnings past expectations
Nov 18, 2025 11:15am
Medtronic clips EU approval for Penditure LAA implant
Oct 2, 2025 12:00pm
